Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers.
Schering AG, Division of Human Pharmacology, Berlin, Germany.
A
A
Kecskés
P
P
Jahn
H
H
Matthes
R K
RK
Kuhlmann
L
L
Lange
D000152:Acne Vulgaris / Q000139:chemically induced; D000279:Administration, Cutaneous; D000287:Administration, Topical; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001624:Betamethasone Valerate / Q000008:administration & dosage / Q000494:pharmacology; D002940:Circadian Rhythm; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009779:Occlusive Dressings; D009824:Ointments; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D009824:Ointments; D001624:Betamethasone Valerate; D002990:Clobetasol; C078007:methylprednisolone aceponate; D006854:Hydrocortisone; D008775:Methylprednisolone